TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: RDEA3170 and Febuxostat Combination Study in Gout Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand the study procedures and the risks involved and is willing to provide written informed consent before the first study-related activity.~* Meets one or more criteria for the diagnosis of gout as per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout.~* Body weight ≥ 50 kg (110 lbs) and a body mass index ≥ 18 and ≤ 45 kg/m2.~* Screening serum urate level ≥ 8 mg/dL.~* Free of any clinically significant disease or medical condition, per the Investigator's judgment.~Exclusion Criteria:~* Unable to take colchicine for gout flare prophylaxis.~* History or suspicion of kidney stones.~* Any gastrointestinal disorder that affects motility and/or absorption.~* Unstable angina, New York Heart Association class III or IV heart failure, ischemic heart disease, stroke, or deep venous thrombosis within 12 months prior to Day 1; or subject is currently receiving anticoagulants.~* Screening laboratory parameters that are outside the normal limits and are considered clinically significant by the Investigator.~* Estimated creatinine clearance \< 60 mL/min calculated by the Cockcroft-Gault formula using ideal body weight during the Screening period.~* Taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked transporter-2 inhibitors; chronic and stable doses are permitted if doses are stable for at least 14 days prior to study medication dosing.~* Unable or unwilling to comply with the study requirements or has a situation or condition that, in the opinion of the Investigator, may interfere with participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RDEA3170 10 mg (Type: EXPERIMENTAL): Once daily (qd) with febuxostat 40mg (qd) for 7 days, and with febuxostat 80 mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
- RDEA3170 15 mg (Type: EXPERIMENTAL): Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
- RDEA3170 5 mg (Type: EXPERIMENTAL): Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
- RDEA3170 2.5 mg (Type: EXPERIMENTAL): Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients more than 18 years-old.~2. Patients diagnosed with NVAF registered in primary care according to ICD-10.~3. Patients initiating apixaban (naïve or VKA experienced), VKA (naïve or VKA experienced), dabigatran or rivaroxaban for the SPAF indication.~4. Continuous enrolment in the 12 months pre-index.~Exclusion Criteria:~1. Patients with valvular heart disease (ICD 10: I05.0-I05.09, I08.0-I08.9) including patients with mitral prosthetic valves.~2. Lost to follow-up (e.g. transfer to primary care center non-ICS).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1. Apixaban (Type: None): Patients who are on treatment with apixaban.~1a. patients who have initiated with apixaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~1b. patients who previously have been treated with VKA in the 12 months before index date.
- Group 2. VKA (Type: None): Patients who are on treatment with VKA.~2a. patients who have initiated with VKA as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~2b. patients who previously have been treated with VKA in the 12 months before index date.
- Group 3. Dabigatran (Type: None): Patients who are on treatment with dabigatran.~3a. patients who have initiated with dabigatran as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~3b. patients who previously have been treated with VKA in the 12 months before index date.
- Group 4. Rivaroxaban (Type: None): Patients who are on treatment with rivaroxaban.~4a. patients who have initiated with rivaroxaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~4b. patients who previously have been treated with VKA in the 12 months before index date.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients with confirmed HER-2 positive , non-operable locally advanced or metastatic breast cancer~* All patients must have received at least 1 but no more than 2 prior anti HER2 based regimens including at least 1 regimen containing Trastuzumab.~* All patients must have at least one measurable lesion as defined by RECIST criteria.~* All patients must have documented progressive disease following the last line of therapy before entering the study~* ECOG Performance status ≤ 1~Exclusion Criteria:~* Patients with known CNS metastasis which are: symptomatic or require treatment for symptom control and/or growing~* Prior treatment with any HSP90 or HDAC inhibitor~* Impaired cardiac function~* Acute or chronic liver or renal disease~* Patients who are currently receiving treatment with any medication which has a relative risk of prolonging the QTc interval or inducing Torsades de Pointes and cannot be switched or discontinued to an alternative drug prior to commencing AUY922~* Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention~* Patients who do not have either an archival tumor sample available or are unwilling to have a fresh tumor sample collected at baseline.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AUY922 + Trastuzumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 1 diabetes mellitus more than one year~* Current treatment: basal (once daily at bedtime) - bolus (three times a day just before main meals) regimen only for at least 12 weeks using a long-acting insulin analogue excluding insulin detemir or intermediate-acting insulin as a basal insulin and NovoRapid® as bolus insulin (a brand of basal insulin preparation has not been changed in the preceding 12 weeks)~* HbA1c below 10.0%~* Body Mass Index (BMI) below 30.0 kg/m\^2~Exclusion Criteria:~* Known hypoglycaemia unawareness or recurrent major hypoglycaemia~* Current treatment with total insulin dose of more than 100 U or IU/day~* Current treatment or expected to start treatment with systemic corticosteroid

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SIBA (Type: EXPERIMENTAL): None
- Insulin Detemir (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 18 years~* On mechanical ventilator more than 7 days~* VAP diagnosis inclusion criteria:~  1. new/progressive infiltration of chest radiography~ 2. 2/3 of the following: 1) fever 2) purulent sputum 3) Wbc \> 12,000 cell/mm3 or \< 4,000 cell/mm3~* Evidence of gram negative bacilli from sputum gram stain or previous sputum culture within 1 week~Exclusion Criteria:~* History of amikacin allergy~* GFR \< 30 mL/min except dialytic patients~* Immunocompromised host: HIV CD4 \< 200 cells/mm3, leukemia, lymphoma, received chemotherapy within 3 weeks, Absolute neutrophil count \< 500/mm3~* Severe ARDS (P/F ratio \< 100)~* Endobronchial obstruction:endobronchial mass, endobronchial stenosis~* Atelectasis~* Severe bronchospasm~* Lung abscess~* Complicated parapneumonic effusion/ Empyema~* Chest trauma~* Uncontrolled extrapulmonary infection(s)~* Received intravenous antibiotic(s) more than 48 hours~* Pregnancy/ Lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nebulized amikacin (Type: EXPERIMENTAL): Amikacin 400 mg nebulized every 12 hours plus intravenous antibiotic(s) for 10 days
- placebo (Type: PLACEBO_COMPARATOR): nebulized placebo every 12 hours plus intravenous antibiotic(s)for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Common Cold Treatment on Cognitive Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Present with symptoms of the common cold of no more than 96 hours duration~* Score of 2 or more on a self-rating for malaise and at least 4 other cold symptoms~Exclusion Criteria:~* Pregnancy or lactation~* Hypersensitivity to drugs~* Have taken caffeine in the last 12 hours or treated their cold

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paracetamol and Caffeine (Type: EXPERIMENTAL): Paracetamol and caffeine
- Paracetamol (Type: ACTIVE_COMPARATOR): Paracetamol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Felzartamab in Late Antibody-Mediated Rejection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntary written informed consent~* Age \>18 years (maximum: 80 years)~* Functioning living or deceased donor allograft after ≥180 days post-transplantation~* eGFR ≥20 ml/min/1.73 m2 (CKD-EPI formula)~* HLA class I and/or II antigen-specific antibodies (preformed and/or de novo DSA).~* Active or chronic/active ABMR (±C4d in PTC) according to the Banff 2019 classification~* Molecular ABMR score (MMDx) ≥0.2~Exclusion Criteria:~* Patients actively participating in another clinical trial~* Age ≤18 years~* Female subject is pregnant or lactating or not on adequate contraceptive therapy~* ABO-incompatible transplant~* Index biopsy results:~* T-cell-mediated rejection classified Banff grade ≥I~* De novo or recurrent severe thrombotic microangiopathy~* Polyoma virus nephropathy~* De novo or recurrent glomerulonephritis~* Acute rejection treatment ≤3 month before screening~* Previous treatment with other CD38 monoclonal antibodies (e.g. daratumumab)~* Previous treatment with other immunomodulatory monoclonal/polyclonal antibodies (e.g. CD20 Ab rituximab, IL-6/IL-6R Ab) ≤3 months before study treatment~* Total bilirubin \>2×the upper limit of normal \[ULN\], alanine transaminase and aspartate aminotransferase \>2·5×ULN~* Haemoglobin \<8 g/dL~* Thrombocytopenia: Platelets \<100 G/L~* Leukopenia: Leukocytes \<3 G/L~* Neutropenia: Neutrophils \< 1.5 G/L~* Hypogammaglobulinemia: Serum IgG \<400 mg/dL~* Active viral, bacterial or fungal infection precluding intensified immunosuppression~* Active malignant disease precluding intensified immunosuppressive therapy~* Latent or active tuberculosis (positive QuantiFERON-TB-Gold test)~* Administration of a live vaccine within 6 weeks of screening~* History of alcohol or illicit substance abuse~* Serious medical or psychiatric illness likely to interfere with participation in the study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Felzartamab (Type: ACTIVE_COMPARATOR): 9 doses of felzartamab as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.
- Placebo (Type: PLACEBO_COMPARATOR): 9 doses of placebo as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with moderate-to-severe chronic plaque psoriasis who has involved body surface area (BSA) ≥ 10% (Palm Method), ≥ 12 on the PASI, and static Physicians Global Assessments (sPGA) ≥ 3 (moderate) at Screening and at BL.~* Patient has had stable psoriatic disease for at least 2 months (ie, without significant changes as defined by the Investigator or designee).~* Patient is a candidate for systemic therapy and the patient has a previous failure, inadequate response, intolerance, or contraindication to at least 1 systemic antipsoriatic therapy including, but not limited to, methotrexate, cyclosporine, psoralen plus ultraviolet light A (PUVA), and ultraviolet light B (UVB).~Exclusion Criteria:~* Patient has prior use of 2 or more biologics for treatment of PsO.~* Patient diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, other skin conditions (eg, eczema), or other systemic autoimmune disorder inflammatory disease at the time of the Screening visit that would interfere with evaluations of the effect of the study drug on psoriasis.~* Patient has prior use of any of the following medications within specified time periods or will require use during the study:~  1. Topical medications within 2 weeks of BL (Week 1).~ 2. PUVA phototherapy and/or UVB phototherapy within 4 weeks prior to the BL Visit.~ 3. Nonbiologic psoriasis systemic therapies (eg, cyclosporine, methotrexate, and acitretin) within 4 weeks prior to the BL Visit.~ 4. Any prior or concomitant or biosimilar adalimumab therapy, either approved or investigational.~ 5. Any systemic steroid in the 4 weeks prior to BL.~Note: Only key inclusion/exclusion criteria mentioned here. Patients will be screened and randomized per the list in the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AVT02 100mg/mL (Adalimumab Biosimilar) (Type: EXPERIMENTAL): Patients will be randomized to AVT02 on 1: 1 basis from the dosing day of Day 1 until week 48
- EU-Humira 100mg/mL (Adalimumab Originator) (Type: EXPERIMENTAL): Patients will be randomized to EU-Humira on 1: 1 basis from the dosing day of Day 1 until week 48

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin Use to Improve the Coagulation Profile in Patients With Venous Thrombosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* Persons with (initial or recurrent) confirmed symptomatic proximal deep vein thrombosis or pulmonary embolism who after a time period of at least 3 to 12 months are allowed to stop, - or stopped using \< 1 month anticoagulant treatment as indicated by their treating physician~* Persons aged 18 years or above~Exclusion Criteria:~* Persons already using statins or lipid lowering drugs, or any other disallowed concomitant medications (erythromycin, HIV protease inhibitors, or cyclosporine)~* History of statin-induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins), including rosuvastatin~* Life expectancy less than 6 months~* Pregnant woman or woman with childbearing potential who are not willing to use contraception~* Active liver or kidney disease or dysfunction or muscle disorders~* Unstable medical or psychological condition that interferes with study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No intervention (Type: NO_INTERVENTION): None
- Rosuvastatin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 DM patients (with HbA1c level \< 8.5 %, BMI kg/m2 ≥ 25, SGPT ≤ 100 IU/L , creatinine ≤ 1.2 mg/dl) of both sexes,~* Aged between 40-50,~* Treated by monotherapy of pioglitazone or metformin.~Exclusion Criteria:~* Patients with diabetes secondary to another cause.~* Patients suffering from serious incurrent illness requiring systemic treatment.~* Patients suffering from any other infectious diseases.~* Patients with impaired kidney function (serum creatinine level more than 1.2mg/dl)~* Patients with impaired hepatic function (SGPT ≥ 100 IU/L).~* Patients with pulmonary insufficiency with hypoxaemia.~* Triglyceriadiamea (TG ≥ 150mg/dl).~* Bloodpressure \> 180 mmHg (Systolic) or \> 110 mmHg (diastolic).~* Positive history of drug or alcohol abuse.~* Pregnant women and willing to be pregnant shortly.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone (001 group) (Type: EXPERIMENTAL): The patients received pioglitazone hydrochloride tablet 30 mg (001 drug)once daily for first three months
- Metformin (002 group) (Type: EXPERIMENTAL): The patients received metformin hydrochloride tablet 850 mg (002 drug)once daily for next three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diabetes type 1 or 2 and gastroparesis~* must be able to understand oral and verbal instructions~Exclusion Criteria:~* gastrointestinal surgery~* other gastrointestinal disease~* S-Creatinine \>150 umol/L~* mental disease~* cerebral disease~* collagen disease~* untreated endocrine disease~* anticholinergic drugs~* psychopharmacologic drugs~* opiates~* addiction to drugs as alcohol and narcotics~* vegetarian

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Diabetic diet (Type: PLACEBO_COMPARATOR): Control group. Subjects with Insulin Treated Diabetes Mellitus and Gastroparesis. Diet: Food of large particle size during 20 weeks.
- Diet food in small particle size (Type: ACTIVE_COMPARATOR): Intervention group: Subjects with Insulin Treated Diabetes and Gastroparesis. Intervention Diet: Food of small particle size during 20 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Hydrocortisone in Acutely Burned Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* males and females,~* between 18 and 75 year old~* who present a burned surface more than 30% of the body surface~* who need catecholamine infusion~* between J0 and J3 after the injury.~Exclusion Criteria:~* pregnancy,~* trauma,~* sepsis,~* cardiac insufficiency,~* AIDS,~* etomidate administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete